Process for improving the therapeutic efficacy of fat-soluble co

Details Process for improving the therapeutic efficacy of fat-soluble co Process for improving the therapeutic efficacy of fat-soluble co

1990-06-13

1993-03-02

Schenkman, Leonard

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

424450, 424455, A61K 3156, A61K 3722

Patent

active

051909367

ABSTRACT:
The process consists in dissolving a corticosteroid in the lipid phase of nonionic amphiphilic lipid vesicles consisting of one or more lipid lamellae.
Composition for carrying out the above process, in which the vesicles are dispersed in an aqueous phase D, have an average diameter of between 10 and 5,000 nm and contain as corticosteroids 17- and/or 21-mono- or -diesters of hydrocortisone, cortisone, prednisone, prednisolone or 6-methylprednisolone, the corticosteroids representing 0.5 to 2.5% by weight of the total lipids of the lamellae.

REFERENCES:
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4772471 (1988-09-01), Vanlerberghe et al.
STN International File Server (Karlsruhe) & Chemical Abstracts. vol. 104, No. 17, Apr. 28, 1986, No. 142371m.
French Search Report on FR 89 07947.

Affiliated with

Also associated with

Rating

Process for improving the therapeutic efficacy of fat-soluble co does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for improving the therapeutic efficacy of fat-soluble co, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for improving the therapeutic efficacy of fat-soluble co will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-126665